<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309802</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-SIUSOM-11-001</org_study_id>
    <nct_id>NCT01309802</nct_id>
  </id_info>
  <brief_title>A Two-Part Study of BOTOX® Therapy for Ischemic Digits</brief_title>
  <official_title>A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Illinois University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern Illinois University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treating patients with Raynaud's phenomenon who have chronic pain and ulcerations is
      extremely challenging. Published reports and our previous work support our hypothesis that
      symptomatic patients experience relief of pain and healing of ulcerations with minimal
      adverse effects when treated with botulinum toxin type A (Btx-A) injections for Raynaud's
      phenomenon. The proposed study is the first clinical trial and prospective study designed to
      document whether or not 1) Btx-A injection relieves pain in a patient's hand affected with
      Raynaud's disease better than a placebo within 28 days of injection, and 2) Btx-A injection
      relieves pain associated with Raynaud's disease for longer than 28 days, improving patients'
      quality of life. Through this study we intend to further determine the effect of injected
      Btx-A on relieving chronic pain and ulcerations to the ischemic hand while characterizing the
      patients for whom this treatment is most effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROJECT SUMMARY OVERVIEW: Treating patients with Raynaud's phenomenon who have chronic pain
      and ulcerations is extremely challenging. Pharmacologic vasodilators and surgical
      sympathectomies offer variable benefits. Case reports, small retrospective outcomes studies,
      and our previous work documenting symptomatic patients treated with botulinum toxin type A
      (Btx-A) injections for Raynaud's phenomenon have demonstrated relief of pain and healing of
      ulcerations with minimal adverse effects. We propose to conduct the first clinical trial and
      prospective study documenting the efficacy of this novel treatment modality.

      STUDY AIMS: The aims of this proposal are to 1) examine the short-term efficacy of Btx-A
      injection compared to placebo in treating pain associated with digit ischemia due to
      Raynaud's disease, and 2) describe the long-term efficacy of Btx-A injection in treating pain
      associated with digit ischemia due to Raynaud's disease by measuring patient satisfaction and
      quality of life changes over time.

      APPROACH: Two groups of patients will be enrolled: Group 1 will consist of patients with
      primary Raynaud's disease (n=20) and Group 2 of patients with secondary Raynaud's (n=20).
      Comparisons between treatment (Btx) and placebo (saline) will occur during the first 28 days
      to determine Btx-A's short-term efficacy. Follow-up visits will occur at Days 7 and 28.
      Post-assessment on Day 28 marks the beginning of the longitudinal observational study of
      patient outcomes. Placebo will no longer be used and patients still suffering from pain will
      be eligible for additional Btx-A injections. Patients may receive up to 4 injections of Btx-A
      during the 1-year study period if pain or ulcerations recur. During the study period
      participants will be followed to collect data on pain-free intervals, ulcer healing,
      subsequent treatment choices, patient satisfaction, and changes in quality of life and hand
      function. Group comparisons will be made to analyze results. Further stratifications for data
      analysis will be made as enrollment numbers allow to control for additional demographic and
      disease variables. Quality-adjusted life-years will be calculated to help determine the
      societal and individual cost of this treatment.

      HYPOTHESIS: We hypothesize that 1) Btx-A injection relieves ischemic pain associated with
      Raynaud's disease better than a placebo within 28 days of injection, and 2) Btx-A injection
      relieves ischemic pain associated with Raynaud's disease for longer than 28 days, improving
      patients' quality of life. Through this study we intend to further elucidate the efficacy of
      injected Btx-A on relieving chronic pain and ulcerations to the ischemic hand while
      characterizing the patients for whom this treatment is most effective. This data will help us
      to apply for national funding to become the coordinating center for a multi-center clinical
      trial. The results of this research have enormous potential to impact millions of patients
      who suffer with Raynaud's phenomenon.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patient Reported Pain-free Days</measure>
    <time_frame>baseline to 28 days</time_frame>
    <description>Subjective pain scales [visual analogue scale (VAS) and faces pain assessment]. Subjects reporting total number of pain free days within the time period of 0-28 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>change from baseline to 28 days</time_frame>
    <description>SF-12v2® Health Survey - Pain Enhanced</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Function</measure>
    <time_frame>baseline to 28 days</time_frame>
    <description>Quick-DASH (Disabilities of the Arm, Shoulder, and Hand) Outcome Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>baseline to 28 days</time_frame>
    <description>The Optum SF-12v2® Health Survey - A Short Patient Reported Survey Measuring Health Using Excellent, Very Good, Good, Fair and Poor Indicators. On a scale from Excellent to Poor, Excellent being the maximum outcome. Good is scored as average. Patient satisfaction assessed as the percentage of participants who responded; Excellent, Very Good and Good on the health survey on average feeling between baseline and 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Perfusion</measure>
    <time_frame>baseline to 28 days</time_frame>
    <description>Doppler perfusion imager and Periscan image analysis software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D A Standardised Patient Reported Measure of Health Status for Clinical and Economic Appraisal</measure>
    <time_frame>baseline to 28 days</time_frame>
    <description>A combined reported score measuring 5 dimensions; mobility, self care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels; no problems, some problems, extreme problems</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Raynaud's Disease</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>onabotulinum toxin type-A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinum toxin type-A</intervention_name>
    <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
    <arm_group_label>onabotulinum toxin type-A</arm_group_label>
    <other_name>BOTOX®</other_name>
    <other_name>botulinum toxin type A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18-75 years

          -  diagnosed with Raynaud's disease/phenomenon

          -  ischemia not due to peripheral artery disease or other vascular disease

          -  otherwise healthy individual

          -  up-to-date tetanus immunization

          -  ability to return/be available for follow-up evaluations

          -  ability/willingness to give informed consent

        Exclusion Criteria:

          -  HIV/AIDS positive or otherwise immunocompromised

          -  history of neuromuscular disease

          -  reported allergy to BOTOX®; reported allergy to lidocaine or other local anesthetic
             agent

          -  ever received botulinum toxin vaccine

          -  ultrasound or angiogram showing digital ischemia due to blocked vessel and not
             Raynaud's disease

          -  history or symptoms of any significant medical problem in the last year (i.e.,
             bradycardia, impaired cardiovascular function, liver disease)

          -  symptoms of infection or illness during initial enrollment

          -  pregnant or lactating women

          -  unable or unwilling to maintain abstinence or use contraception for 28 days following
             all injections

          -  cognitive impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Neumeister, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Illinois University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allergan.com/products/medical_dermatology/botox.htm</url>
    <description>Allergan product website</description>
  </link>
  <link>
    <url>http://www.fda.gov/Drugs/default.htm</url>
    <description>U.S. Food and Drug Administration</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails</url>
    <description>Drugs@FDA; U.S. Food and Drug Administration</description>
  </link>
  <reference>
    <citation>Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 Dec;35(12):2085-92. doi: 10.1016/j.jhsa.2010.09.019.</citation>
    <PMID>21134617</PMID>
  </reference>
  <reference>
    <citation>Neumeister MW, Chambers CB, Herron MS, Webb K, Wietfeldt J, Gillespie JN, Bueno RA Jr, Cooney CM. Botox therapy for ischemic digits. Plast Reconstr Surg. 2009 Jul;124(1):191-201. doi: 10.1097/PRS.0b013e3181a80576.</citation>
    <PMID>19568080</PMID>
  </reference>
  <reference>
    <citation>Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Invest. 2004 Apr;34(4):312-3.</citation>
    <PMID>15086364</PMID>
  </reference>
  <reference>
    <citation>Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007 Jan;119(1):217-26.</citation>
    <PMID>17255677</PMID>
  </reference>
  <reference>
    <citation>Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. J Hand Surg Am. 2009 Mar;34(3):446-52. doi: 10.1016/j.jhsa.2008.11.026.</citation>
    <PMID>19258141</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <results_first_submitted>July 28, 2016</results_first_submitted>
  <results_first_submitted_qc>April 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>botox</keyword>
  <keyword>raynaud's</keyword>
  <keyword>botulinum toxin</keyword>
  <keyword>botulinum toxin A</keyword>
  <keyword>raynaud's disease</keyword>
  <keyword>raynaud's syndrome</keyword>
  <keyword>raynaud's phenomenon</keyword>
  <keyword>ischemic digits</keyword>
  <keyword>ischemia</keyword>
  <keyword>botox treatment</keyword>
  <keyword>onabotulinum</keyword>
  <keyword>onabotulinum toxin</keyword>
  <keyword>onabotulinum toxin type A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not be sharing data.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>no intervention</description>
        </group>
        <group group_id="P2">
          <title>Onabotulinum Toxin Type-A</title>
          <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>no intervention</description>
        </group>
        <group group_id="B2">
          <title>Onabotulinum Toxin Type-A</title>
          <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" lower_limit="24" upper_limit="73"/>
                    <measurement group_id="B2" value="49.2" lower_limit="26" upper_limit="70"/>
                    <measurement group_id="B3" value="51.3" lower_limit="24" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patient Reported Pain-free Days</title>
        <description>Subjective pain scales [visual analogue scale (VAS) and faces pain assessment]. Subjects reporting total number of pain free days within the time period of 0-28 days.</description>
        <time_frame>baseline to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>no intervention</description>
          </group>
          <group group_id="O2">
            <title>Onabotulinum Toxin Type-A</title>
            <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patient Reported Pain-free Days</title>
          <description>Subjective pain scales [visual analogue scale (VAS) and faces pain assessment]. Subjects reporting total number of pain free days within the time period of 0-28 days.</description>
          <units>percentage of pain free days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>SF-12v2® Health Survey - Pain Enhanced</description>
        <time_frame>change from baseline to 28 days</time_frame>
        <population>Data were not collected,</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>no intervention</description>
          </group>
          <group group_id="O2">
            <title>Onabotulinum Toxin Type-A</title>
            <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>SF-12v2® Health Survey - Pain Enhanced</description>
          <population>Data were not collected,</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hand Function</title>
        <description>Quick-DASH (Disabilities of the Arm, Shoulder, and Hand) Outcome Measure</description>
        <time_frame>baseline to 28 days</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>no intervention</description>
          </group>
          <group group_id="O2">
            <title>Onabotulinum Toxin Type-A</title>
            <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
          </group>
        </group_list>
        <measure>
          <title>Hand Function</title>
          <description>Quick-DASH (Disabilities of the Arm, Shoulder, and Hand) Outcome Measure</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>The Optum SF-12v2® Health Survey - A Short Patient Reported Survey Measuring Health Using Excellent, Very Good, Good, Fair and Poor Indicators. On a scale from Excellent to Poor, Excellent being the maximum outcome. Good is scored as average. Patient satisfaction assessed as the percentage of participants who responded; Excellent, Very Good and Good on the health survey on average feeling between baseline and 28 days.</description>
        <time_frame>baseline to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>no intervention</description>
          </group>
          <group group_id="O2">
            <title>Onabotulinum Toxin Type-A</title>
            <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>The Optum SF-12v2® Health Survey - A Short Patient Reported Survey Measuring Health Using Excellent, Very Good, Good, Fair and Poor Indicators. On a scale from Excellent to Poor, Excellent being the maximum outcome. Good is scored as average. Patient satisfaction assessed as the percentage of participants who responded; Excellent, Very Good and Good on the health survey on average feeling between baseline and 28 days.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tissue Perfusion</title>
        <description>Doppler perfusion imager and Periscan image analysis software</description>
        <time_frame>baseline to 28 days</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>no intervention</description>
          </group>
          <group group_id="O2">
            <title>Onabotulinum Toxin Type-A</title>
            <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue Perfusion</title>
          <description>Doppler perfusion imager and Periscan image analysis software</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D A Standardised Patient Reported Measure of Health Status for Clinical and Economic Appraisal</title>
        <description>A combined reported score measuring 5 dimensions; mobility, self care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels; no problems, some problems, extreme problems</description>
        <time_frame>baseline to 28 days</time_frame>
        <population>not were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>no intervention</description>
          </group>
          <group group_id="O2">
            <title>Onabotulinum Toxin Type-A</title>
            <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D A Standardised Patient Reported Measure of Health Status for Clinical and Economic Appraisal</title>
          <description>A combined reported score measuring 5 dimensions; mobility, self care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels; no problems, some problems, extreme problems</description>
          <population>not were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>no intervention</description>
        </group>
        <group group_id="E2">
          <title>Onabotulinum Toxin Type-A</title>
          <description>up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Broken bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Collapsed Lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Redness, Bleeding</sub_title>
                <counts group_id="E1" events="35" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" events="31" subjects_affected="14" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Swelling, Tenderness, Bruising</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness, Drowsiness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dry Eyes, Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Increased Cough, Runny nose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Allergic Reaction or Itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Difficulty Swallowing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Temporary Weakness or numbness of muscle</sub_title>
                <counts group_id="E1" events="32" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Administrator</name_or_title>
      <organization>Southern Illinois University School of Medicine</organization>
      <phone>217-545-2531</phone>
      <email>surgeryresearch@siumed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

